Allogeneic SCT for myeloma may be curative for young patients, but its role remains controversial because of a reported high TRM in some series. Since 1991, we have performed 25 allografts for myeloma using fully matched sibling donors. Of the 18 evaluable patients, 13 achieved CR at a median time of 2.5 months post-transplant. The five patients who were not in CR when assessed at 3 months received a short course of a-interferon and four subsequently achieved CR with this approach at a median of 82 days. One patient who failed to respond to IFN went on to achieve CR after four doses of DLI therapy, thus giving an overall CR rate of 72%. Seven patients have relapsed at a median of 4.7 years post-transplant (range 1.38-7.7 years) including two patients who had received IFN therapy. In five of these cases, relapse has been as a localised area of bone disease or isolated plasmacytoma with no evidence of marrow involvement by trephine biopsy or molecular analysis. All patients with localised relapse were treated with local radiotherapy 7DLI and four are currently disease free despite two patients having had further treatment for a second localised lesion. Six patients died of TRM (24%) and the OS at 8 years is currently 69% with an EFS of 26%. These results suggest that allogeneic SCT for myeloma can be carried out with an acceptable TRM and a high CR rate. However, late relapses as localised disease may be a frequent finding and may represent foci of myeloma not eradicated by the conditioning. The use of pretransplant MRI scanning and top-up radiotherapy to involved areas may be useful in preventing this type of relapse. Allogeneic transplantation for multiple myeloma has been shown to result in a high CR rate and is thought to be curative for a proportion of individuals. However, conventional allografts for myeloma have remained controversial owing to the high reported TRM rates which has led to superior survival being demonstrated for patients undergoing autologous transplants compared to allografts.
myeloma; allogeneic transplant; relapse; localised plasmacytoma Allogeneic transplantation for multiple myeloma has been shown to result in a high CR rate and is thought to be curative for a proportion of individuals. 1 However, conventional allografts for myeloma have remained controversial owing to the high reported TRM rates which has led to superior survival being demonstrated for patients undergoing autologous transplants compared to allografts. 2 Although recent data suggest that there has been a major improvement in survival of conventional myeloma allografts since 1994 owing to a significant reduction in transplant-related mortality, 3 many centres are instead exploring the use of nonmyeloablative allogeneic transplants for patients with myeloma. In principle, this should be associated with a low transplant-related mortality, relying on the potent graft-versus-myeloma effect to elicit a cure. However, the relapse risk of this approach is still unknown. Indeed, relapse remains a major concern even after conventional allografts for myeloma, where it is estimated to be 45% at 5 years 1 and with no apparent plateau in the relapse rate being seen on the most recent EBMT registry analysis. 3 In our series of 25 patients receiving conventional myeloablative-matched sibling allografts for myeloma, we have observed seven cases of relapsed disease. In five of these cases relapse occurred late, as an isolated osteolytic lesion or solitary plasmacytoma without evidence of marrow involvement. A review of the literature suggests that similar localised or extramedullary relapse has been observed by several other authors after allogeneic transplantation for myeloma and may, in fact, be a frequent finding. [4] [5] [6] [7] [8] [9] Patients and methods A total of 25 patients who received allogeneic transplants from matched-sibling donors for multiple myeloma (n ¼ 23) or plasma cell leukaemia (n ¼ 2) in a single centre from 1991 to 2000 were studied. Patient characteristics are shown in Table 1 . Some of these patients have been reported previously, 10, 11 but the series is now larger and the followup more mature. The median age of the patients was 48.2 years (range 34-58 years) and 13 patients were in first plateau phase, while 11 had more advanced disease and one was refractory to chemotherapy. Conditioning was with high dose melphalan 110 mg/m 2 in 24 patients together with TBI (12 Gy in six fractions). One 58-year-old patient received a lower dose of melphalan 70 mg/m 2 . GVHD prophylaxis was with cyclosporine A and a short course of MTX, as previously described. 10, 11 Eight patients also received additional top-up radiotherapy of up to 40 Gy to sites of major bony disease identified by skeletal survey. The source of stem cells was bone marrow in 13 patients and G-CSF mobilised PBSC in 12 patients and the median cell dose infused was 2.99 Â 10 8 MNC/kg (range 1.2-18.4). The median follow-up of the patients is 5.3 years (range 1.5-10.3 years).
All patients underwent fluorescent PCR for IgH rearrangements using DNA extracted from bone marrow samples pretransplant. Informative patients were monitored for MRD using this technique at intervals posttransplant and at the time that relapse was diagnosed. Details of the method used have been given previously. 12 Response to treatment was defined according to the EBMT criteria and CR required negative immunofixation of serum and/or urine. 13 
Results

Transplant-related toxicity
There have been six deaths from transplant-related causes, giving a relatively low overall actuarial transplant-related mortality of 24% (Figure 1 ) as previously reported using this conditioning. 11 Four of these deaths were related to infection; three because of respiratory viruses (2 RSV and 1 Influenza A) and one secondary to a fungal pneumonia. One patient died of a cerebral haemorrhage and there was 1 GVHD-related death at 3 months post-transplant. Five of the deaths occurred before day +100 while one of the RSV-related deaths occurred 6 months post-transplant.
Disease response
Among the 25 patients, 20 were analysed for disease response at 3 months post-transplant. Of these, 15/20 had achieved CR at a median of 2.5 months. The five patients still not in CR at 4 months when CSA had been discontinued were commenced on a short course of ainterferon at a dose of 3 MGU Â 3/week. 12 Four patients subsequently achieved CR following IFN therapy at a median of 82 days (range 42-252 days). One patient failed to respond to IFN and eventually achieved CR after four doses of DLI therapy.
GVHD
Eight out of 21 evaluable patients who engrafted developed acute GVHD of which seven were Grade 1 and one Grade 4. Seven out of 18 evaluable patients at 6 months had evidence of chronic GVHD. In six of these patients this was limited and in one patient it developed after the addition of adjuvant IFN therapy. Similarly, the one patient with extensive chronic GVHD had previously received adjuvant IFN therapy to induce remission.
Relapse
Seven patients have relapsed at a median of 4.7 years posttransplant (range 1.38-7.7 years). Details of the relapse cases are given in Table 2 . Two of the patients who relapsed had received additional pretransplant top-up radiotherapy to areas of bony disease identified pretransplant, but the subsequent relapse did not involve these sites. Interestingly, five out of the seven cases of relapse have occurred as localised disease either with a solitary plasmacytoma or lytic bone lesion with no evidence of generalised marrow disease by immunohistochemical analysis of trephine biopsy specimens using V38, CD138 or kappa and lambda antibodies. In addition, there was no evidence for a clonal population of plasma cells in the trephine biopsy using molecular analysis for IgH rearrangements in any of the four patients with localised relapse that were studied. Biopsies from the sites of relapse confirmed reappearance of the original IgH clone in 2/2 of patients where material was available for study.
In four of these five patients with apparent localised relapse, there was an associated low level recurrence of the original serum or urinary paraprotein, while one patient had no detectable monoclonal component. MRI scans were not performed on these patients with apparent isolated relapses to look for evidence of bony involvement at other sites. However, repeat skeletal surveys were done which showed no overt evidence of other new lytic lesions.
Treatment for the patients with isolated relapse has mainly been with radiotherapy combined with DLI, although one patient received additional thalidomide while another with minor lytic bony lesions received thalidomide alone. Responses were seen in four of these patients who achieved a second CR, although two have subsequently gone on to develop a second site of localised disease at intervals of 12 and 20 months after the first relapse. Following further treatment with combined radiotherapy and DLI, both these patients responded and currently remain well and disease free. One patient continued to excrete a small amount of Bence Jones protein in the urine and has subsequently developed amyloidosis and died of complications related to this. Radiographs demonstrating some of these areas of localised disease are shown in Figure 2 .
Two patients had evidence of generalised relapse with morphological and molecular evidence of marrow involvement. One of these had initially presented with plasma cell leukaemia, and despite further chemotherapy she failed to respond and died. The second patient had a combination of low-level marrow disease together with localised lytic bone lesions and plasmacytomas that developed consecutively despite further treatment with systemic chemotherapy, radiotherapy to localised sites of disease, DLI and thalidomide. This culminated in the development of cord compression and multiple skin plasmacytomas, which were refractory to treatment and resulted in the patient's demise.
Five of the patients who relapsed did so despite the development of either acute GVHD (n ¼ 3, all Grade 1), chronic GVHD (n ¼ 1) or a combination of acute and chronic GVHD (n ¼ 1), which required treatment. Both patients who developed chronic GVHD had done so after receiving a short course of interferon therapy in order to induce CR. Figure 3 shows the cumulative relapse risk for this group of patients receiving allogeneic transplants for multiple myeloma and shows no evidence of a plateau. It can be seen that many of these relapses occurred late (median of 4.2 years) and that some of these patients with localised disease appeared to be salvaged with further aggressive therapy giving an overall survival at 8 years of 72% (Figure 4) . 
Discussion
This analysis of a series of 25 patients undergoing conventional TBI-based allogeneic transplantation for multiple myeloma confirms the existing data that, although this procedure may be curative for some individuals, relapse remains a significant problem. 1 There is unfortunately no evidence for improvement in the relapse rate with time unlike the situation for transplant-related mortality that has decreased significantly over the past decade leading to improved overall survival for patients allografted for this disease. 3 Previous studies have shown that failure to achieve CR after allogeneic transplantation is a major factor in predicting relapse, 1 but even in patients who have achieved CR the relapse risk remains approximately 20% at 2 years 3 and continues to rise with time. In our study, all patients achieved CR after allografting, although five patients required additional treatment with a-interferon or DLI therapy in order to achieve this. We observed evidence of relapse in seven patients, which occurred between 1.38 and 8.52 years post-transplant (median of 4.2 years) resulting in a cumulative relapse risk of 59% at 8 years ( Figure 3 ) with no evidence of plateau. The delay of some of these relapses is worthy of specific comment and seems to be particularly common following allografts for myeloma since similar observations have been reported by other workers (see below). This contrasts with allogeneic transplantation for other haematological malignancies where relapse within 24 months of transplant is more usual. [14] [15] [16] This finding confirms the need for extended follow-up of such patients before estimates of disease-free survival are calculated.
Interestingly, five of the seven cases of relapse appeared to involve localised areas of disease with either osteolytic lesions or solitary plasmacytomas. It may be speculated that these areas may represent persisting foci of disease not eradicated by the conditioning or that they arise in sites that are immunologically privileged and somehow escape the graft-versus-myeloma effect. Indeed, 3/4 patients with localised relapse had experienced previous GVHD, which did not appear to prevent such relapses. A search of the literature reveals that similar findings have been observed by other workers. Case reports of relapse with isolated osteolytic lesions, 4 subcutaneous, 5 or soft-tissue 7 plasmacytomas have been described, many of which have occurred late -up to 7 years post-transplant. In addition, a large study of extramedullary relapse of haematological malignancies following allogeneic transplantation included three cases of isolated soft-tissue plasmacytoma occurring between 30 and 51 months post-transplant in patients with multiple myeloma. 8 This study suggested that extramedullary relapse was relatively resistant to graft-versus-tumour effects with poor responses to DLI. These data are in keeping with a report by Zomas et al 6 who described a patient treated with DLI for frank marrow relapse post allogeneic transplant in whom there was complete response of the systemic disease but the patient subsequently went on to develop subcutaneous plasmacytomas. However, responses to adoptive immunotherapy may be variable since there is at least one report of localised myelomatous relapse responding to DLI in the literature. 5 Alternative treatment options for localised relapse may also be considered, since a recent report describes the successful use of thalidomide therapy in four patients with myeloma who relapsed 3-4 years post allograft with predominantly extramedullary disease. 9 It is also of interest to note that there was no evidence of molecular disease by IgH PCR, monitoring in any of the four patients presented with localised relapse in whom it was studied. Indeed, the value of PCR monitoring in the detection of early relapse postallograft for myeloma must be questioned in the light of these findings. None of these cases of relapse would have been detected by routine posttransplant molecular monitoring, whereas the reappearance of the original serum or urinary paraprotein was observed in 4/5 cases at relapse and may therefore be a better marker of this type of late relapse. There is little published information on patterns of relapse following allogeneic transplantation for myeloma and our findings suggest that late localised relapse may, in fact, be a frequent, but poorly recognised, finding. Further aggressive therapy involving localised radiotherapy, DLI and/or thalidomide is warranted as this may enable some of these patients to be salvaged and re-enter CR, although further localised relapses are possible. The contribution of pretransplant foci of bony disease in leading to such areas of localised relapse is not clear, but the use of MRI scanning and the addition of top-up radiotherapy to these sites pretransplant may be of benefit in preventing such relapses and should be explored. Furthermore, if graftversus-myeloma effects are not capable of preventing the development of late extramedullary relapses, then the current interest in using nonmyeloablative conditioning regimens for myeloma should be viewed with caution.
